Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
March 1st, 2008
Cadence Pharmaceuticals, Inc. (NASDAQ:CADX) a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced that Cadence has received commitments from selected investors to purchase up to 9,240,307 shares of Cadence's common stock at a purchase price of $5.34 per share pursuant to an effective shelf registration statement. The closing of the offering is expected to take place on February 20, 2008. The total number of shares to be sold in the offering may be reduced to 8,056,716 and the gross proceeds may be reduced to $43.0 million pursuant to Nasdaq Marketplace...
Source: Law & Health Weekly (2008-03-01)
|
